Australia markets open in 5 hours 40 minutes

Firebrick Pharma Limited (FRE.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2000-0.0050 (-2.44%)
At close: 02:41PM AEDT

Firebrick Pharma Limited

440 Collins Street
Level 10
Melbourne, VIC 3000
1300 301 874

IndustryDrug Manufacturers—General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Peter Laurence Molloy BSc, FAICD, MBAFounder, Exec. Chairman & CEO324.3kN/A1954
Dr. Stephen Francis Goodall MASc, MBAFounder, COO & Exec. Director250.43kN/AN/A
Mr. Kavi Bekarma B.Sc., C.A.Chief Financial OfficerN/AN/AN/A
Dr. Simon TuckerChief Scientific OfficerN/AN/AN/A
Ms. Robyn BraniganHead of MarketingN/AN/AN/A
Prof. Peter FriedlandChief Medical OfficerN/AN/AN/A
Dr. Monique BaldwinHead of Regulatory AffairsN/AN/AN/A
Mr. Stephen BuckleyCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Corporate governance

Firebrick Pharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.